<DOC>
	<DOCNO>NCT00002785</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . Bone marrow transplantation may allow doctor give high dos chemotherapy kill cancer cell . Radiation therapy use high-energy x-rays damage cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy , bone marrow transplantation , radiation therapy treat infant acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy , Bone Marrow Transplantation , Radiation Therapy Treating Infants With Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I. Assess feasibility outcome intensify induction/consolidation follow intensified re-induction/re-intensification infant less 1 year age newly diagnose acute lymphocytic leukemia ( ALL ) . II . Evaluate feasibility outcome bone marrow transplantation use family unrelated donor infant 11q23 abnormality . III . Evaluate neuropsychologic outcome upon completion protocol therapy patient reach age 3 7 year , special attention outcome infant receive total-body irradiation . IV . Study biology infant ALL sample leukemic blood bone marrow . V. Study possible association among patient- disease-specific factor family sociodemographic characteristic mediate treatment outcome . OUTLINE : Upon completion Induction/Intensification Re-Induction therapy , patient 11q23 abnormality match one-antigen mismatch relate unrelated donor proceed immediately Transplantation ; others proceed Re-Intensification , Consolidation , Intensified Maintenance , Routine Maintenance . The following acronym use : AlBM Allogeneic Bone Marrow ARA-C Cytarabine , NSC-63878 ASP Asparaginase , NSC-109229 CF Leucovorin calcium , NSC-3590 CTX Cyclophosphamide , NSC-26271 CYSP Cyclosporine , NSC-290193 DM Dexamethasone , NSC-34521 DNR Daunorubicin , NSC-82151 G-CSF Granulocyte-Colony Stimulating Factor ( Amgen ) , NSC-614629 HC Hydrocortisone , NSC-10483 MePRDL Methylprednisolone , NSC-19987 Mesna Mercaptoethane sulfonate , NSC-113891 MP Mercaptopurine , NSC-755 MTX Methotrexate , NSC-740 PEG-ASP Pegaspargase , NSC-644954 PRED Prednisone , NSC-10023 TBI Total-Body Irradiation TIT Triple Intrathecal Therapy ( IT ARA-C/IT HC/IT MTX ) VCR Vincristine , NSC-67574 VH Very High Dose VP-16 Etoposide , NSC-141540 INDUCTION/INTENSIFICATION : 5-Drug Combination Systemic Chemotherapy follow 3-Drug Combination Systemic Chemotherapy plus 3-Drug Combination Intrathecal Chemotherapy . DM/VCR/DNR/CTX/Mesna/ASP ; follow MTX/CF/VP-16/CTX/Mesna ; plus TIT . RE-INDUCTION : 5-Drug Combination Systemic Chemotherapy plus 3-Drug Combination Intrathecal Chemotherapy . DNR/VCR/CTX/Mesna/ASP/DM ; plus TIT . RE-INTENSIFICATION : 2-Drug Combination Systemic Chemotherapy plus Single-Agent Intrathecal Chemotherapy follow 2-Drug Combination Systemic Chemotherapy . VCR/VH MTX/CF ; plus IT ARA-C ; follow VP-16/CTX/Mesna . CONSOLIDATION : 2-Drug Combination Systemic Chemotherapy follow 2-Drug Combination Systemic Chemotherapy plus Single-Agent Intrathecal Chemotherapy . ARA-C/ASP ; follow VH MTX/CF/VCR ; plus IT ARA-C . INTENSIFIED MAINTENANCE : 4-Drug Combination Systemic Chemotherapy plus Single-Agent Intrathecal Chemotherapy follow 2-Drug Combination Systemic Chemotherapy . DM/VCR/MTX/MP ; plus IT ARA-C follow VP-16/CTX/Mesna . ROUTINE MAINTENANCE : 4-Drug Combination Systemic Chemotherapy plus Single-Agent Intrathecal Chemotherapy . VCR/MTX/MP/PRED ; plus IT MTX . TRANSPLANTATION : 2-Drug Combination Myeloablative Chemotherapy follow Radiotherapy follow Hematopoietic Rescue plus GVHD Prophylaxis . ARA-C/CTX ; follow TBI use linear accelerator Co60 equipment ; follow AlBM ; plus MePRDL ; CYSP . PROJECTED ACCRUAL : 100 patient per year enter approximately 3 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm acute lymphoblastic leukemia ( ALL ) infants 12 month age diagnosis Adequate bone marrow and/or peripheral blood specimen blast available No prior treatment ALL except emergency therapy following : Blast cell crisis Superior vena cava syndrome Renal failure due leukemic infiltration kidney PATIENT CHARACTERISTICS : See General Eligibility Criteria</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Year</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
</DOC>